New scan may spot liver scarring without needle biopsy
NCT ID NCT06252610
First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This study tests whether a combined PET/MRI scan can detect and measure liver scarring (fibrosis) in people with primary sclerosing cholangitis (PSC). Ten participants will receive two experimental tracers that bind to scar tissue, and results will be compared to standard tests like FibroScan. The goal is to improve non-invasive diagnosis and avoid the need for liver biopsies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School
Charlestown, Massachusetts, 02129, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outperform standard care for a rare liver disease in teens?
- Could a new molecule tame a rare liver disease? early safety trial begins
- Blood test may tame the tightrope walk of transplant drugs
- Artificial intelligence may help decide who gets a liver first
- AI may outsmart current system for liver transplant priority
- Could a common drug stop a rare liver disease from returning after transplant?